HomeNDC LookupRxCUI directory › RxCUI 1601390

Palbociclib 125 MG Oral Capsule [Ibrance] — RxCUI 1601390

RxNorm drug concept · Semantic branded drug
RxCUI 1601390 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 3 package NDCs Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1601390
Official namePalbociclib 125 MG Oral Capsule [Ibrance]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asIbrance 125 MG Oral Capsule
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)1,422 prescriptions · 14 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Palbociclib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Palbociclib is not traditional chemotherapy. It's a targeted therapy that works specifically on proteins called CDK4 and CDK6, which breast cancer cells need in order to divide and...
  • What exactly is palbociclib (Ibrance) treating — is it a chemotherapy?
  • Palbociclib very commonly lowers your white blood cell count — especially the neutrophils that fight bacterial infections. Low neutrophils can leave you vulnerable to serious infec...
  • Why do I need blood tests so often while taking this medicine?
📖 Read our full Palbociclib guide →

🕸️ Concept Web — How Palbociclib 125 MG Oral Capsule [Ibrance] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Palbociclib 125 MG Oral Capsule [Ibrance] RxCUI 1601390

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Palbociclib 1601374
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ibrance 1601381
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Palbociclib Oral Capsule 1601379
    • Palbociclib Oral Product 1601377
    • Palbociclib Pill 1601378
    • Palbociclib Oral Capsule [Ibrance] 1601383
    • Ibrance Oral Product 1601384
    • Ibrance Pill 1601385
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Palbociclib 125 MG Oral Capsule SCD · 1601388
  • Palbociclib 125 MG SCDC · 1601387
  • Palbociclib Oral Capsule SCDF · 1601379
  • Palbociclib Oral Product SCDG · 1601377
  • Palbociclib Pill SCDG · 1601378

Brand-Name Concepts

  • Palbociclib 125 MG [Ibrance] SBDC · 1601389
  • Palbociclib Oral Capsule [Ibrance] SBDF · 1601383
  • Ibrance Oral Product SBDG · 1601384
  • Ibrance Pill SBDG · 1601385
  • Ibrance BN · 1601381

📦 FDA Products & Package NDCs

3 products · 3 package NDCs
3 package NDCs map to RxCUI 1601390 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00069-0187-21 21 CAPSULE in 1 BOTTLE (0069-0187-21) Ibrance Pfizer Laboratories Div Pfizer Inc 2015-02-03
00069-0188-21 21 CAPSULE in 1 BOTTLE (0069-0188-21) Ibrance Pfizer Laboratories Div Pfizer Inc 2015-02-03
00069-0189-21 21 CAPSULE in 1 BOTTLE (0069-0189-21) Ibrance Pfizer Laboratories Div Pfizer Inc 2015-02-03
Observed labelers: Pfizer Laboratories Div Pfizer Inc (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.